Disease States / Health

Adiponectin as a potential biomarker of PCOS in young, lean women

Adiponectin as a Potential Biomarker of Polycystic Ovarian Syndrome in Young, Lean WomenThe association between Polycystic Ovarian Syndrome (PCOS) and low adiponectin levels has been noted in previous studies. However, these studies assumed low levels were due to obesity, a common ailment within women with PCOS.

A recent case-control study, published in the Journal of Ovarian Research has been conducted to investigate the role of adiponectin in young, lean women who have PCOS. The study created two sub-groups of women who were analysed and classified as follows:

  1. 75 PCOS patients aged between 16 – 35 years with a Body Mass Index of  <23
  2. 75 healthy subjects aged between 16 -35 years with a Body Mass Index of <23 (selected from family and friends of sub-group 1)

Researchers tested participants for fasting glucose, total cholesterol, high-density lipoprotein (HDL), insulin, adiponectin and androgen levels. Insulin Resistance was then calculated using homeostasis model assessment for insulin resistance (HOMA-IR). Logistical regression was used to determine association between adiponectin and PCOS after adjusting for co-variants.

Researchers used multivariable analysis and made adjustments for factors such as age, BMI, family history, total cholesterol, HDL and Insulin Resistance. Results showed participants with PCOS (sub-group one) were 3.2 times more likely to show low adiponectin levels compared to that of participants in second sub-group.

When comparing participants with a family history of PCOS against those without any family history those with were significantly more likely to have lower adiponectin (OR = 3.32, 95% CL 1.2 – 8.6, p-value 0.014). Associations of Insulin Resistance and low adiponectin levels were still statistically apparent even after covariate adjustments were made.

Conclusions drawn from this study identified that adiponectin levels are independently associated with PCOS and can only be partly explained by insulin resistance. Adiponectin could potentially be used as a biomarker when assessing young lean women with fewer symptoms of PCOS. It could also be used as a screening test for women with a family history of PCOS.

Reference: Journal of Ovarian Research, Feb 2014

The Randox Research division has a multitude of tests designed to aid in metabolic and nutrition research. Our Metabolic Syndrome Array II tests for adiponectic as well as Cystatin C and C-Reactive Protein allowing for multiplex analysis. For more information see Metabolic and Nutrition Research Brochure or e-mail research@randox.com

Leave a Reply

Your email address will not be published. Required fields are marked *